Patients with inflammatory bowel disease (IBD) treated with anti-TNF therapy have attenuated serological responses to vaccination against SARS-CoV-2, which is associated with increased risk of breakthrough infection.3, 4, 5, 6 However, even in anti-TNF recipients, vaccine-induced antibody responses are highly heterogeneous. This evidence concerns the gene TNF and inflammatory bowel disease.